April 5, 2023

The U.S. Food and Drug Administration (FDA) released draft guidance — Marketing Submission Recommendations for a Predetermined Change Control Plan (PCCP) for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions — with public comments due July 3.

The document describes information provided by manufacturers that would enable FDA consideration of planned AI/ML software modifications during device marketing submissions. The PCCP enables downstream improvements to AI/ML software functionality without necessitating additional submissions, provided the future modifications are implemented in accordance with the FDA-vetted plan.

The American College of Radiology® (ACR®) is reviewing the draft guidance. Members interested in providing feedback for potential inclusion in ACR’s future comments should contact Michael Peters, ACR Senior Government Affairs Director.


Related ACR News

  • ACR Advocates Changes to Improve IPPS, OPPS

    ACR submitted official comments to the Centers for Medicare and Medicaid Services in response to the agency’s RFI related to the FY 2026 Hospital Inpatient Prospective Payment System.

    Read more
  • ACR Provides Recommendations About Fed Health Tech Programs

    The College’s feedback is in response to the government’s request for information regarding the health technology ecosystem.

    Read more
  • ACR Drives Results at June AMA House of Delegates Meeting

    The ACR team engaged in policy discussions, helping to shape the future of healthcare and ensure the voice of radiology is heard loud and clear.

    Read more